[1]
Schlesinger, T., Lebwohl, M., Del Rosso, J., Patel, V.A., Kircik, L., Armstrong, A., Berman, B., Rigel, D., Narayanan, S., Koscielny, V., Kasujee, I. and Bhatia, N. 2023. Safety and Tolerability of Tirbanibulin 1% Treatment of Actinic Keratosis on Face and Scalp in Routine Clinical Practice Across the U.S. (PROAK Study). SKIN The Journal of Cutaneous Medicine. 7, 6 (Nov. 2023), s263. DOI:https://doi.org/10.25251/skin.7.supp.263.